Sacco Rodolfo, Tapete Gherardo, Simonetti Natalia, Sellitri Rossella, Natali Veronica, Melissari Sara, Cabibbo Giuseppe, Biscaglia Lilia, Bresci Giampaolo, Giacomelli Luca
Department of Gastroenterology, Pisa University Hospital, Pisa.
University of Palermo, Palermo.
J Hepatocell Carcinoma. 2017 Jul 27;4:105-110. doi: 10.2147/JHC.S103661. eCollection 2017.
According to the current European Association for the Study of Liver guidelines, transarterial chemoembolization (TACE) is the recommended first-line therapy for patients with intermediate-stage (Barcelona Clinic Liver Cancer-B class) hepatocellular carcinoma (HCC). The efficacy of this therapy is supported by robust evidence; however, there is still a lack of standardization in treatment methodology, and TACE protocols are widely variable. Moreover, TACE can be associated with a number of contraindications. Despite these limitations, research on TACE is still ongoing with the aim of optimizing the use of this methodology in the current management of HCC. In particular, TACE represents a control in comparative studies, and it is currently being investigated in combination schemes, for example, with sorafenib. In this review, we briefly describe the current scenario and the clinical innovations regarding TACE for the treatment of HCC.
根据当前欧洲肝脏研究协会的指南，经动脉化疗栓塞术（TACE）是中期（巴塞罗那临床肝癌-B期）肝细胞癌（HCC）患者推荐的一线治疗方法。该疗法的疗效有充分证据支持；然而，治疗方法仍缺乏标准化，TACE方案差异很大。此外，TACE可能有多种禁忌症。尽管有这些局限性，但仍在进行关于TACE的研究，目的是在当前HCC治疗中优化该方法的使用。特别是，TACE在比较研究中作为对照，目前正在研究其联合方案，例如与索拉非尼联合。在这篇综述中，我们简要描述了TACE治疗HCC的当前情况和临床创新。
